L-Università ta' Malta

Centre for Molecular Medicine & Biobanking
University of Malta
Msida MSD 2080, Malta

Tel: +356 2340 2280
cmmb@um.edu.mt

www.um.edu.mt

APPENDIX B

Complete if any of the following will be performed: immunisations; biological fluid collections; tumour passage or induction; human tissue; and/or the use of biohazardous agents.

1. If immunizations will be used, please list:

Species	
Primary Immunogen	
Booster Adjuvant	
Route of Administration Adjuvant	
Injection Site	
Volume per Site	
Number of Sites Injected	
Number of Boosters	
Frequency of Boosters	

2. If biological fluids (blood, lymph, bile, CSF, etc.) will be collected, please specify (unless they are nonsurvival procedures):

Species	
Types of Fluid Collected	
Volume and Frequency of Collection	
Site of Collection	

3. If tumour injection into animals (including hybridoma inoculation for monoclonal antibody production) from animal to animal will be made:

   a. Please specify:

Species Inoculated	
Species of Tumour Origin	
Inoculation Site	
Endpoint of Harvest/Passage and source of cells	

   b. Indicate priming agent, dosage and route of administration;

   _____

   _____

   _____

   c. If tumour passages will be made, please indicate explicitly whether or not cell lines or tumours have been tested and found to be free of rodent viruses and/or mycoplasmas:

   _____

   _____

   _____

   d. With respect to tumour induction procedures (for acquisition of cells or study of tumour response), please specify:

Route of Tumour Development	
Site of Species	
Carcinogen	
Administration	
Type	

4. For projects employing radioactive materials, infectious agents, recombinant DNA, the final approval will not be granted until the protocol has been approved by the appropriate Committee(s).

Will radioactive materials be used in live animals? Yes ☐ No ☐

If yes, please list:

a. Species Exposed: _____

b. Identity, quantity (mCi) & half-life of Radioactive materials used: _____

_____

_____

5. Will infectious agents be used in live animals? Yes ☐ No ☐

If yes, please list:

a. Species Exposed and susceptibility:

_____

b. Biological Agents(s) and possible effects:

_____

_____

6. Will there be recombinant DNA animal studies? Yes ☐ No ☐

If yes, state what agent or method was used

_____

7. Will carcinogens or hazardous chemical agents be used in live animals? Yes ☐ No ☐

If yes, please list:

a. Species Exposed: _____

b. Agents(s): _____

_____

_____

8. Will human tissues be used in live animals? Yes ☐ No ☐

If using human tissue, has it been tested for human pathogens? Yes ☐ No ☐

9. For projects employing radioactive materials, infectious agents, hazardous chemical agents, recombinant DNA, carcinogenics, and/or human tissue, please describe:

a. Expected clinical effects: _____

_____

_____

b. Expected mortality: _____

_____

_____

c. Endpoint: _____

_____

_____

10. Will viral gene delivery be employed in live animals? Yes ☐ No ☐

11. Will temporary gene function modifications be affected in live animals? Yes ☐ No ☐

_____ _____

Principal Investigator (Applicant) Date

_____ _____

Veterinarian's Signature Date

_____ _____

Chairperson's Signature Date